跳至主要内容
临床试验/NCT00599768
NCT00599768已完成不适用

Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 个研究点目标入组 325 人开始时间: 2008年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
325
主要终点
Determine the optimal cut-off score of ID Pain-T Questionnaire for screening of neuropathic pain

研究概览

简要总结

This prospective cohort and multi-site study aims to develop Taiwan version (ID Pain-T) based on the original versions of ID Pain and also DN4, and validate both ID Pain-T and DN4 applied in Taiwanese subjects at the clinical setting.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects without headache pain over 30 days and at least 18 years old who will visit the clinic, inclusive of male and female.
  • Subjects who are able to complete the ID Pain-T Questionnaire.

排除标准

  • Subjects who are illiterate or unable to complete questionnaire.
  • Subjects who are currently participating in another study or have participated in another pain study within one month of study entry.
  • Subjects with low back pain are unable to participate in this study; as the sciatica caused by the piriformis (exclusive of the other types of sciatic pain), lumbago, unclear identification in nerve injury (e.g. complex regional pain syndrome type I) or mixed origin (e.g. cancer pain).

结局指标

主要结局

Determine the optimal cut-off score of ID Pain-T Questionnaire for screening of neuropathic pain

时间窗: end of study

次要结局

  • Evaluate the predictive power of ID Pain-T Questionnaire for diagnosis of neuropathic pain(end of study)
  • Develop and evaluate validity of a short form diagnostic tool based on DN4 structure(end of study)

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

相似试验